Kuna RS, Girada SB, Asalla S, Vallentyne J, Maddika S, Patterson JT, Smiley DL, DiMarchi RD, Mitra P: Glucagon-like peptide-1 receptor-mediated endosomal cAMP generation promotes glucose-stimulated insulin secretion in pancreatic ncreatic
This study was limited in scope: Conducted on 24 rats, not humans Administered a single dose Designed only to demonstrate that some absorption is possible Importantly, the study itself includes this disclaimer: This proof-of-concept study is not intended to provide guidance on the sublingual dosing of semaglutide in humans, or dosing conversion from other forms to sublingual administration. This means the only research behind these products cannot confirm whether they work in humans or provide guidance on appropriate dosing
45,74 In summary, expanding practical guidance for the management of GI adverse effects is critical to ensuring treatment continuity and maximizing clinical benefit
Nausea affected 17-22% on tirzepatide vs 18% on semaglutide